5 recruiting, 4 active not recruiting, 1 completed, 1 not yet recruiting. 9 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Recruiting 4, Active not recruiting 3, Completed 1, Terminated 1 |
| Phase 2 | 3 | Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
Follow Metastatic Endometrial Carcinoma: new trials by email Literature Review of Metastatic Endometrial Carcinoma trials Research Report on Metastatic Endometrial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer Biospecimen Collection, Computed Tomography, Elacestrant - Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma | Phase 2 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 50 | 2026-12-18 | 2026-06-09 |
| A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors TJ037130 - Solid Tumor, Metastatic Ovary Cancer | Phase 1 | Recruiting | TJ Biopharma Co., Ltd. | 128 | 2026-10-30 | 2026-10-19 |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NKT3964, Paclitaxel, Doxorubicin - Solid Tumor, Advanced Solid Tumor | Phase 1 | Recruiting | NiKang Therapeutics, Inc. | 238 | 2024-09-19 | 2026-10-16 |
| Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform Biospecimen Collection, Tissue Collection - Early Stage Triple-Negative Breast Carcinoma, Metastatic Bladder Urothelial Carcinoma | Recruiting | Mayo Clinic | 324 | 2024-04-24 | 2026-03-12 | |
| A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NKT3447 - Solid Tumor, Solid Tumor, Adult | Phase 1 | Terminated | NiKang Therapeutics, Inc. | 23 | 2024-02-23 | 2025-09-25 |
| Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers Biopsy Procedure, Biospecimen Collection, Cobimetinib - Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 42 | 2023-09-14 | 2026-10-09 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel - Advanced Breast Carcinoma, Advanced Endometrial Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 43 | 2022-04-29 | 2026-07-16 |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Cyclophosphamide, Neoantigen Peptide Vaccine, Pembrolizumab - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 138 | 2022-03-31 | 2026-08-20 |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial Biopsy Procedure, Biospecimen Collection, Ceralasertib - Advanced Breast Carcinoma, Advanced Colon Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 51 | 2021-08-09 | 2026-09-04 |
| Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Malignant Peritoneal Neoplasm, Malignant Retroperitoneal Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 26 | 2018-09-21 | 2025-05-22 |
| Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate - Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 82 | 2018-04-16 | 2026-09-09 |
| VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer Biopsy, Computed Tomography, Fluorine F 18 Tetrafluoroborate - Metastatic Endometrial Carcinoma, Recurrent Endometrial Adenocarcinoma | Phase 1 | Active not recruiting | Mayo Clinic | 34 | 2017-09-15 | 2026-07-21 |
Endometrial Neoplasms (12) · Carcinosarcoma (5) · Neoplasm Metastasis (5) · Ovarian Neoplasms (5) · Stomach Neoplasms (4) · Carcinoma, Hepatocellular (3) · Carcinoma, Renal Cell (3) · Fallopian Tube Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Uterine Cervical Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Small Cell Lung Carcinoma (2) · Uterine Diseases (2)
Female Urogenital Diseases (12) · Female Urogenital Diseases and Pregnancy Complications (12) · Genital Diseases (12) · Genital Diseases, Female (12) · Genital Neoplasms, Female (12) · Neoplasms (12) · Neoplasms by Site (12) · Urogenital Diseases (12) · Urogenital Neoplasms (12) · Uterine Neoplasms (12) · Uterine Diseases (10) · Digestive System Diseases (8) · Digestive System Neoplasms (8) · Adnexal Diseases (6) · Neoplasms by Histologic Type (6)
Specimen Handling (7) · Magnetic Resonance Spectroscopy (6) · Biopsy (5) · Nivolumab (2) · cabozantinib (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Blood Specimen Collection (1) · CTLA-4 Antigen (1) · Colony-Stimulating Factors (1) · Cyclophosphamide (1) · Doxorubicin (1) · Everolimus (1) · Immunoglobulin G (1) · Ipilimumab (1)
Mayo Clinic (3) · National Cancer Institute (NCI) (3) · M.D. Anderson Cancer Center (2) · NiKang Therapeutics, Inc. (2) · Jonsson Comprehensive Cancer Center (1) · TJ Biopharma Co., Ltd. (1)
United States (11) · Canada (1) · China (1) · South Korea (1)
Amir A Jazaeri (1) · Apostolia M Tsimberidou (1) · Dev Mukhopadhyay, PhD (1) · Jamie N. Bakkum-Gamez, M.D. (1) · Jordyn Silverstein, MD (1) · Joyce F Liu (1) · Kanwal P Raghav (1) · Stephanie Lheureux (1) · Yanyan Lou, MD, PhD (1)
PMID 35288469, PMID 38471508, PMID 40791544, PMID 41484629
R01CA207240 (1), UM1CA186644 (1), UM1CA186688 (1), UM1CA186709 (1)